This is the Novartis study, now in phase 2.A 18-month Study to...

This is the Novartis study, now in phase 2.

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease - Full Text View - ClinicalTrials.gov


This other one is in the phase 1:

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD) - Full Text View - ClinicalTrials.gov

In Clinical trials there are 3060 different Parkinson's disease studies listed. ATH is not the only one there. 150 M is a lot of money, but perhaps not so much if the potential is very, very high. UCB started this study 1 year ago and they calculated that they need 300 patients who take the drug for 1.5 years to see the difference in this phase 2 study. To get to the market, a phase 3 study is needed in this diagnosis. So there is a lot of work to be done before this drug UCB0599 is on the market.

But there are 3060 different Parkinson's studies listed in Clinical trials, ATH is not there alone, neither is UCB or Novartis. ATH434 is an iron chelator and if you look at the studies listed as an iron chelator and Parkinson disease, you will find only 2 studies, both done with deferiprone. So ATH is an iron chelation company, they believe that a safe iron chelator as 434 can help PD or in the first phase MSA. When we investors are investing in ATH we are investing in the hypothesis that iron chelation works. In this field, there are not many companies, I think ATH is the only one now in the phase 2 study.
But iron accumulation is a problem in old people, not only in the brain. ATH434 is tested also in other indications, as was told in the annual report.
My prediction is that ATH434 will be in the market clearly before this UCB0599 if the ATH434 study will get positive results, only phase 2 is needed.